<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="222715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00183729</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH064196-02</org_study_id>
    <secondary_id>K23MH064196-02</secondary_id>
    <nct_id>NCT00183729</nct_id>
  </id_info>
  <brief_title>Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults</brief_title>
  <official_title>Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes
      and preventing major depressive disorder in older adults who have been admitted to a
      rehabilitation hospital for a hip fracture or cardiopulmonary condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is a serious medical illness that is often difficult to diagnose and treat. It
      occurs in people of all ages, but is often overlooked in older adults. Depression frequently
      co-occurs with other serious illnesses, and may be mistaken by both patients and health care
      givers as a normal consequence of the illness. However, these misconceptions toward
      depression contribute to the underdiagnosis and undertreatment of depressive disorders in
      older people. In turn, depression may hinder a patient's recovery from an illness. This
      study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and
      preventing major depressive disorder in older adults who have been admitted to a
      rehabilitation hospital for a hip fracture or a cardiopulmonary condition.

      This double-blind study will last for 12 months. Participants will be randomly assigned to
      receive either placebo or memantine, which is a drug that is often used to treat Alzheimer's
      disease. Both memantine and placebo will be administered to participants for 12 weeks. All
      participants will be followed for an additional 40 weeks. Outcome measurements will include
      participants' depressive symptoms, motivation, and learned helplessness. In addition,
      medication side effects, functional outcome, and incidence of major depressive disorder will
      be measured. All measurements will be taken at Week 12 and Month 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive Symptoms</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>Hamilton depression rating scale ; scale ranges 0 (no symptoms) to 52 (severe depression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Depressive Disorder</measure>
    <time_frame>Measured at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Recovery</measure>
    <time_frame>Measured at Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Memantine (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memantine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.</description>
    <arm_group_label>Memantine (1)</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo distribution is planned to mimic the active drug.</description>
    <arm_group_label>Placebo (2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to a skilled nursing facility for rehabilitation within 3 months of recent
             disabling medical event (e.g., hip fracture)

          -  Medically stable (e.g., no active seizures, delirium, unstable pulse/blood pressure)

        Exclusion Criteria:

          -  Aphasia or cognitive impairments sufficiently severe to prevent valid assessment
             (e.g., a score of less than 22 on the Mini Mental State Examination)

          -  Current major depressive episode

          -  History of or current psychosis or mania

          -  Current substance or alcohol abuse or dependence (within 3 months of study entry)

          -  Current use of memantine

          -  Sensitivity or contraindication to memantine

          -  End-stage kidney, liver, heart, or lung disease

          -  Recent hemorrhagic stroke

          -  A FIM score of greater than 70 (on a 91 point scale)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J. Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry. 2012 Sep;27(9):974-80. doi: 10.1002/gps.2813. Epub 2011 Dec 16.</citation>
    <PMID>22173933</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 20, 2016</lastchanged_date>
  <firstreceived_date>September 14, 2005</firstreceived_date>
  <firstreceived_results_date>July 1, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Rehabilitating</keyword>
  <keyword>Elderly</keyword>
  <keyword>Apathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study has small sample size and is unlikely to be useful for data sharing efforts; however, interested researchers can contact the first author via email.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>35 subjects were randomized</recruitment_details>
      <pre_assignment_details>No significant events. Please see Lenze et al, Int J of Geriatric Psychiatry 2012 article for details.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Memantine (1)</title>
          <description>Memantine for 12 weeks
Memantine: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (2)</title>
          <description>Placebo for 12 weeks
Placebo: Placebo distribution is planned to mimic the active drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantine (1)</title>
          <description>Memantine for 12 weeks
Memantine: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (2)</title>
          <description>Placebo for 12 weeks
Placebo: Placebo distribution is planned to mimic the active drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.1" spread="9.7"/>
                    <measurement group_id="B2" value="78" spread="9.2"/>
                    <measurement group_id="B3" value="79.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depressive Symptoms</title>
        <description>Hamilton depression rating scale ; scale ranges 0 (no symptoms) to 52 (severe depression)</description>
        <time_frame>Measured at Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine (1)</title>
            <description>Memantine for 12 weeks
Memantine: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (2)</title>
            <description>Placebo for 12 weeks
Placebo: Placebo distribution is planned to mimic the active drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Depressive Symptoms</title>
          <description>Hamilton depression rating scale ; scale ranges 0 (no symptoms) to 52 (severe depression)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.6"/>
                    <measurement group_id="O2" value="13.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1.5"/>
                    <measurement group_id="O2" value="5.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Depressive Disorder</title>
        <time_frame>Measured at Week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Recovery</title>
        <time_frame>Measured at Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Memantine (1)</title>
          <description>Memantine for 12 weeks
Memantine: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (2)</title>
          <description>Placebo for 12 weeks
Placebo: Placebo distribution is planned to mimic the active drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Lenze</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-1671</phone>
      <email>lenzee@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
